Paid Clinical Trials in Billings, MT
As of July 2026, 135 paid clinical trials are recruiting in Billings, Montana. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Billings offers studies at sites including Billings Clinic Cancer Center for conditions such as Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia, Stage IV Lung Cancer AJCC v8, Chronic Lymphocytic Leukemia. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Billings
Trials by drug in Billings
Filter results
134 clinical trials
↓ Download CSVEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
About research studies in Billings
Billings has approximately 135 recruiting research studies across a wide range of therapeutic areas. Montana hosts a diverse network of universities, academic medical centers, and community hospitals that run clinical trials across oncology, cardiology, neurology, and many other therapeutic areas.
Top Research Study Locations in Billings
Researchers run research studies in Billings, MT at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Billings Clinic Cancer Center | Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia, Stage IV Lung Cancer AJCC v8 | 93 |
| Saint Vincent Frontier Cancer Center | Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | 20 |
| Saint Vincent Healthcare | Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | 13 |
| Intermountain Health West End Clinic | Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | 8 |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana | Melanoma Stage IV, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma | 8 |
| Billings Clinic | Cystic Fibrosis, Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 2 | 5 |
| St. Vincent Frontier Cancer Center-Research | Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer | 4 |
| St. Vincent Frontier Cancer Center | Chronic Lymphocytic Leukemia, Leukemia, B-cell, Leukemia, Lymphocytic | 3 |
| Billings Clinic - Billings | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypertension | 1 |
| Billings Clinic | Hypothyroidism | 1 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC) | 1 |
| GSK Investigational Site | Multiple Myeloma, Newly Diagnosed Multiple Myeloma | 1 |
| Intermountain Health - Intermountain Health West End Clinic | Ovarian Cancer | 1 |
| Intermountain Health - St. Vincent Frontier Cancer Center | KRAS G12C-mutated Solid Tumors, Lung Cancer, KRAS, NRAS, HRAS-mutated NSCLC, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer | 1 |
| Intermountain Health Saint Vincent Regional Hospital | Cervical Cancer | 1 |
| Intermountain Health West End Clinic- Gynecologic Oncology | Cervical Cancer | 1 |
| Intermountain Healthcare | Early Breast Cancer | 1 |
| Massive Bio SYNERGY-AI site | BRCA Gene Rearrangement, Bladder Cancer, Breast Cancer | 1 |
| Montana Cancer Consortium NCORP | Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma | 1 |
| SCL Health - Cancer Centers of Montana | Breast Cancer | 1 |
| Saint Joseph Hospital - Cancer Centers - St. Vincent Frontier Cancer Center | Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Pancreatic Cancer | 1 |
| Saint Vincent Regional Hospital- Cancer Centers of Montana | Cervical Cancer | 1 |
| St Vincent Frontier Cancer Center | Marginal Zone Lymphoma, Relapsed/Refractory Follicular Lymphoma | 1 |
| St. Vincent Cancer Center | Non-Small Cell Lung Cancer | 1 |
| St. Vincent Gynecologic Oncology | Ovarian Cancer | 1 |
Active & Upcoming Studies in Billings (2026)
Recruiting trials in Billings grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (116 active studies)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations · Phase 3 · SWOG Cancer Research Network
- A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) · Phase 3 · Merck Sharp & Dohme LLC
Vaccines (1 active study)
Mental health & behavior (1 active study)
- Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program · Phase 3 · Alliance for Clinical Trials in Oncology
Diabetes & metabolic (1 active study)
Neurology & pain (1 active study)
Cardiovascular (1 active study)
Common conditions studied in Billings
- Stage IVB Prostate Cancer AJCC v8 (7 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Acute Myeloid Leukemia (6 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Stage IV Lung Cancer AJCC v8 (6 active studies). Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens.
- Chronic Lymphocytic Leukemia (5 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Ovarian Cancer (5 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Stage IIIB Lung Cancer AJCC v8 (5 active studies). Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens.
Leading research sponsors in Billings
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- NRG Oncology
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Montana are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Montana research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Billings. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Billings
Hipa.ai aggregates every recruiting study in Billings from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Billings?
There are approximately 135 recruiting clinical trials in Billings, Montana listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Billings pay participants?
Most recruiting trials in Billings compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Billings?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Billings?
The most common conditions under active study in Billings include Stage IVB Prostate Cancer AJCC v8 (7), Acute Myeloid Leukemia (6), Stage IV Lung Cancer AJCC v8 (6), Chronic Lymphocytic Leukemia (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Billings?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Billings on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Billings?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Billings?
Recruiting research sites in Billings include Billings Clinic Cancer Center, Saint Vincent Frontier Cancer Center, Saint Vincent Healthcare, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Billings right now?
The largest active categories in Billings are Cancer & tumors (116), Vaccines (1), Mental health & behavior (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.